Viridian Therapeutics, Inc.DE
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $70.8M | $302,000 | $314,000 | $1.8M | $3.0M |
| Selling, general & administrative | $95.3M | $61.1M | $95.0M | — | — |
| Research and development | $338.9M | $238.3M | $159.8M | $100.9M | $56.9M |
| Operating expenses | $434.2M | $299.3M | $254.8M | $136.1M | $82.7M |
| Operating income | -$363.4M | -$299.0M | -$254.4M | -$134.3M | -$79.7M |
| Interest expense | $4.9M | $2.2M | $1.3M | $500,000 | $3,000 |
| Income tax expense | $0 | — | — | — | — |
| Net income | -$342.6M | -$269.9M | -$237.7M | -$129.9M | -$79.4M |
| Balance Sheet | |||||
| Current assets | $894.2M | $738.5M | $486.5M | $431.2M | $200.2M |
| Total assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M |
| Current liabilities | $70.7M | $47.9M | $26.6M | $33.3M | $13.6M |
| Total liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M |
| Stockholders' equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$276.4M | -$232.3M | -$184.2M | -$93.8M | -$54.6M |
| Depreciation and amortization | $460,000 | $540,000 | $522,000 | $255,000 | $120,000 |
| Stock-based compensation | $44.3M | $42.1M | $67.2M | $19.8M | $14.5M |
| Capital expenditure | $495,000 | $511,000 | $898,000 | $797,000 | $338,000 |
| Free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | -$54.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 103.1M · Free float 19.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.